NEW YORK (GenomeWeb News) – Genomic Health said after the close of the market on Monday that it is exclusively licensing Almac Group's technology and intellectual property to develop a multi-gene test for the prediction of benefits from DNA damage-based chemotherapy drugs.

Genomic Health will also validate and validate the test, which is focused on drugs such as the commonly used anthracycline-based regimens. The company said such a test would be especially useful for high-risk breast cancer patients who are eligible for chemotherapy based on their Oncotype DX score.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.